Detalles de la búsqueda
1.
New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer.
Br J Cancer
; 125(3): 380-389, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34035435
2.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med
; 379(8): 753-763, 2018 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30110579
3.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Cancer
; 125(22): 3974-3984, 2019 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31318460
4.
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 620, 2019 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31234810
5.
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 517, 2019 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31146717
6.
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Lancet
; 387(10021): 866-73, 2016 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-26686313
7.
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Cancer
; 121(20): 3639-48, 2015 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26111104
8.
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.
Lancet
; 383(9917): 603-13, 2014 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24224997
9.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Lancet
; 384(9938): 164-72, 2014 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24529560
10.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet Oncol
; 15(6): 640-7, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24657003
11.
Adjuvant trastuzumab in HER2-positive breast cancer.
N Engl J Med
; 365(14): 1273-83, 2011 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-21991949
12.
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.
Oncologist
; 18(7): 812-8, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23814044
13.
Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator.
BMC Cancer
; 13: 197, 2013 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-23597096
14.
Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades.
Arch Gynecol Obstet
; 288(6): 1203-12, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24190694
15.
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
Ann Surg Oncol
; 19(5): 1508-16, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22193884
16.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Lancet Oncol
; 12(7): 631-41, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21641868
17.
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Lancet Oncol
; 12(4): 369-76, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21429799
18.
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer.
Clin Cancer Res
; 28(9): 1854-1862, 2022 05 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35110416
19.
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet
; 375(9712): 377-84, 2010 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20113825
20.
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
Lancet
; 376(9735): 91-102, 2010 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20570343